PDF(Pubmed)
Abstract：
UNASSIGNED: Anti-vascular endothelial growth factor (VEGF) treatment through intravitreal or subretinal administrations has been proven effective for VEGF-driven pediatric vitreoretinal diseases but are not feasible for advanced cases, such as shallow traction retinal detachments or peripheral circumferential retinal detachments which adhere to the lens. Intra-anterior chamber injection (IAcI) of anti-VEGF may be a viable alternative in such cases but needs evaluation.
UNASSIGNED: To investigate the effects and safety of IAcI of anti-VEGF to treat VEGF-driven pediatric vitreoretinal diseases.
UNASSIGNED: This was a retrospective observational case series study conducted at Xinhua Hospital, affiliated with Shanghai Jiao Tong University School of Medicine in China. The study included 14 eyes of 13 children diagnosed with vitreoretinal disease exhibiting elevated vascular activity between January and August 2023.
UNASSIGNED: IAcI with ranibizumab.
UNASSIGNED: Retinal vascular abnormalities, vitreous hemorrhage resolution, and complications 1 month and 3 months after injection.
UNASSIGNED: Of 13 patients included in this study, 12 were male. The mean age was 4.6 years (range, 1 month to 9 years). Six patients were diagnosed with familial exudative vitreoretinopathy, 4 with morning glory syndrome, 1 with retinopathy of prematurity, and 2 with chronic retinal detachments of unknown causes. At 1-month postoperative follow-up, vascular activity had decreased in 14 of 14 eyes. At 3-month follow-up, vascular activity had resolved in 7 of 14 eyes, persisted in 6 of 14 eyes, and reactivated in 1 of 14 eyes. On final observation, no complications were reported.
UNASSIGNED: These findings support the possibility of treatment using IAcI with ranibizumab to decrease retinal vascular abnormalities in familial exudative vitreoretinopathy or retinopathy of prematurity or related conditions, but further studies are needed to understand more precise benefits and risks. This approach might be considered in cases where intravitreal or subretinal injection are not feasible, recognizing the limitations of these findings and that longer-term outcomes still need to be monitored.
UNASSIGNED: To investigate the effects and safety of IAcI of anti-VEGF to treat VEGF-driven pediatric vitreoretinal diseases.
UNASSIGNED: This was a retrospective observational case series study conducted at Xinhua Hospital, affiliated with Shanghai Jiao Tong University School of Medicine in China. The study included 14 eyes of 13 children diagnosed with vitreoretinal disease exhibiting elevated vascular activity between January and August 2023.
UNASSIGNED: IAcI with ranibizumab.
UNASSIGNED: Retinal vascular abnormalities, vitreous hemorrhage resolution, and complications 1 month and 3 months after injection.
UNASSIGNED: Of 13 patients included in this study, 12 were male. The mean age was 4.6 years (range, 1 month to 9 years). Six patients were diagnosed with familial exudative vitreoretinopathy, 4 with morning glory syndrome, 1 with retinopathy of prematurity, and 2 with chronic retinal detachments of unknown causes. At 1-month postoperative follow-up, vascular activity had decreased in 14 of 14 eyes. At 3-month follow-up, vascular activity had resolved in 7 of 14 eyes, persisted in 6 of 14 eyes, and reactivated in 1 of 14 eyes. On final observation, no complications were reported.
UNASSIGNED: These findings support the possibility of treatment using IAcI with ranibizumab to decrease retinal vascular abnormalities in familial exudative vitreoretinopathy or retinopathy of prematurity or related conditions, but further studies are needed to understand more precise benefits and risks. This approach might be considered in cases where intravitreal or subretinal injection are not feasible, recognizing the limitations of these findings and that longer-term outcomes still need to be monitored.
摘要：
通过玻璃体内或视网膜下给药的抗血管内皮生长因子（VEGF）治疗已被证明对VEGF驱动的小儿玻璃体视网膜疾病有效，但对晚期病例不可行。如浅牵引视网膜脱离或附着在晶状体上的周边环状视网膜脱离。在这种情况下，前房内注射（IAcI）抗VEGF可能是可行的替代方法，但需要进行评估。
■目的研究抗VEGF的IAcI治疗VEGF驱动的小儿玻璃体视网膜疾病的效果和安全性。
■这是一项在新华医院进行的回顾性观察性病例系列研究，隶属于中国上海交通大学医学院。该研究包括2023年1月至8月期间被诊断患有玻璃体视网膜疾病的13名儿童的14只眼，表现出血管活动升高。
■IAcI与雷珠单抗。
■视网膜血管异常，玻璃体出血消退，注射后1个月和3个月出现并发症。
■本研究纳入的13名患者中，12是男性。平均年龄为4.6岁(范围，1个月至9年）。6例患者被诊断为家族性渗出性玻璃体视网膜病变，4患有牵牛花综合症，1患有早产儿视网膜病，2例原因不明的慢性视网膜脱离。术后1个月随访,14只眼中的14只眼血管活性下降。在3个月的随访中，14只眼中的7只血管活动已经消退，坚持14只眼睛中的6只，并在14只眼睛中的1只重新激活。最后的观察,无并发症报告.
这些发现支持使用IAcI联合雷珠单抗治疗减少家族性渗出性玻璃体视网膜病变或早产儿视网膜病变或相关疾病的视网膜血管异常的可能性，但是需要进一步的研究来了解更准确的益处和风险。在玻璃体内或视网膜下注射不可行的情况下，可以考虑这种方法。认识到这些发现的局限性，并且仍然需要监测长期结果。
■目的研究抗VEGF的IAcI治疗VEGF驱动的小儿玻璃体视网膜疾病的效果和安全性。
■这是一项在新华医院进行的回顾性观察性病例系列研究，隶属于中国上海交通大学医学院。该研究包括2023年1月至8月期间被诊断患有玻璃体视网膜疾病的13名儿童的14只眼，表现出血管活动升高。
■IAcI与雷珠单抗。
■视网膜血管异常，玻璃体出血消退，注射后1个月和3个月出现并发症。
■本研究纳入的13名患者中，12是男性。平均年龄为4.6岁(范围，1个月至9年）。6例患者被诊断为家族性渗出性玻璃体视网膜病变，4患有牵牛花综合症，1患有早产儿视网膜病，2例原因不明的慢性视网膜脱离。术后1个月随访,14只眼中的14只眼血管活性下降。在3个月的随访中，14只眼中的7只血管活动已经消退，坚持14只眼睛中的6只，并在14只眼睛中的1只重新激活。最后的观察,无并发症报告.
这些发现支持使用IAcI联合雷珠单抗治疗减少家族性渗出性玻璃体视网膜病变或早产儿视网膜病变或相关疾病的视网膜血管异常的可能性，但是需要进一步的研究来了解更准确的益处和风险。在玻璃体内或视网膜下注射不可行的情况下，可以考虑这种方法。认识到这些发现的局限性，并且仍然需要监测长期结果。
